Polymeric nanocarriers for transport modulation across the pulmonary epithelium: Dendrimers, polymeric nanoparticles, and their nanoblends

AAPS Journal

Volumn 16, Issue 3, 2014, Pages 522-538

  Bharatwaj, Balaji ^a   Dimovski, Radovan ^a   Conti, Denise S ^a   Da Rocha, Sandro R P ^a  

^a Wayne State University   (United States)

Author keywords

Calu 3; dendrimers; nanoblends; nanoparticles; oral inhalation; pressurized metered dose inhalers; transport modulation

Indexed keywords

AMINE TERMINATED GENERATION 3 POLY(AMIDO AMINE) DENDRIMER; DENDRIMER; FLUORESCEIN ISOTHIOCYANATE; NANOCARRIER; NANOPARTICLE; UNCLASSIFIED DRUG; LACTIC ACID; PAMAM STARBURST; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER;

AEROSOL; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ELECTRON MICROSCOPY; ENCAPSULATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INHALER; INTERNALIZATION; LUNG ALVEOLUS EPITHELIUM; METERED DOSE INHALER; PERMEABILITY; RESPIRATORY EPITHELIUM; ACTIVE TRANSPORT; CELL LINE; CHEMISTRY; LUNG; METABOLISM; PARTICLE SIZE; RESPIRATORY TRACT MUCOSA;

BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; DENDRIMERS; HUMANS; LACTIC ACID; LUNG; METERED DOSE INHALERS; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; RESPIRATORY MUCOSA;

EID: 84900297843     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9588-5     Document Type: Article

References (59)

1. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74. doi:10.1038/nrd2153. (Pubitemid 46020287)
2. Andrade F, Rafael D, Videira M, Ferreira D, Sosnik A, Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev. 2013. doi:10.1016/j.addr.2013.07.020.
3. Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Thera Deliv. 2013;4(8):1047-72. doi:10.4155/tde.13.71.
4. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev. 2006;58(9-10):1030-60. doi:10.1016/j.addr.2006.07.012. (Pubitemid 44712023)
5. Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules - principles, problems, and examples. Journal of physiology and pharmacology. Official J Polish Phys Soc. 2008;59 Suppl 6:53-79.
6. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. European Resp J. 2011;37(6):1308-31. doi:10.1183/09031936.00166410.
7. Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting beta agonists for the treatment of asthma: clearing the air. Thorax. 2012;67(4):342-9. doi:10.1136/thx.2010.155648.
8. Rogueda PG, Traini D. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Exp Opinion Drug Deliv. 2007;4(6):595-606. (Pubitemid 350193398)
9. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Exp Opinion Drug Deliv. 2008;5(6):629-39. doi:10.1517/17425247.5.6.629. (Pubitemid 351998253)
10. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002;99(19):12001-5. doi:10.1073/pnas.182233999.
11. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotech. 2007;25(12):563-70. doi:10.1016/j.tibtech.2007.09.005. (Pubitemid 350138179)
12. Bai S, Thomas C, Rawat A, Ahsan F. Recent progress in dendrimer-based nanocarriers. Critical Rev Thera Drug Carrier Sys. 2006;23(6):437-95. (Pubitemid 46568172)
13. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2013;42(3):1147-235. doi:10.1039/c2cs35265f.
14. Kitchens KM, El-Sayed ME, Ghandehari H. Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev. 2005;57(15):2163-76. doi:10.1016/j.addr.2005.09.013. (Pubitemid 41759391)
15. Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, Verberkmoes JL, et al . Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicro Agents Chemother. 2010;54(4):1436-42. doi:10.1128/AAC.01471-09.
16. Petros RA, DeSimone JM. Strategies in the design of nan-oparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-27. doi:10.1038/nrd2591.
17. Saad M, Garbuzenko OB, Ber E, Chandna P, Khandare JJ, Pozharov VP, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? Official J Controlled Release Soc. 2008;130(2):107-14. doi:10.1016/j.jconrel.2008.05.024.
18. Jevprasesphant R, Penny J, Attwood D, D'Emanuele A. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. Official J Controlled Release Soc. 2004;97(2):259-67. doi:10.1016/j.jconrel. 2004.03.022. (Pubitemid 38759483)
19. Mignani S, El Kazzouli S, Bousmina M, Majoral JP. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev. 2013. doi:10.1016/j.addr.2013.01.001.
20. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. International J Pharm. 2003;259(1-2):143-60. (Pubitemid 36638561)
21. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials. 2009;30(14):2790-8. doi:10.1016/j.biomaterials.2009.01.057.
22. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. ACS J Surf Colloids. 2005;21(19):8852-7. doi:10.1021/la0502084. (Pubitemid 41396646)
23. Grainger CI, Greenwell LL, Lockley DJ, Martin GP, Forbes B. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res. 2006;23(7):1482-90. doi:10.1007/s11095-006-0255- 0. (Pubitemid 43993811)
24. Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers - toward improved particle characterization in the lung. Pharm Res. 2003;20(5):788-96. (Pubitemid 36515312)
25. Grainger CI, Greenwell LL, Martin GP, Forbes B. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. Official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2009;71(2):318-24. doi:10.1016/j.ejpb. 2008.09.006.
26. Perumal OP, Inapagolla R, Kannan S, Kannan RM. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterial s. 2008;29(24-25):3469-76. doi:10.1016/j.biomaterials.2008.04.038.
27. Wu L, Bharatwaj B, Panyam J, da Rocha SR. Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants. Pharm Res. 2008;25(2):289-301. doi:10.1007/s11095-007-9466-2. (Pubitemid 351257982)
28. Conti DS, Bharatwaj B, Brewer D, da Rocha SR. Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. Official J Controlled Release Soc. 2012;157(3):406-17. doi:10.1016/j.jconrel.2011.09.089.
29. Majoros IJ, Thomas TP, Mehta CB, Baker Jr JR. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem. 2005;48(19):5892-9. doi:10.1021/jm0401863. (Pubitemid 41324600)
30. Kim Y, Klutz AM, Jacobson KA. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem. 2008;19(8):1660-72. doi:10.1021/bc700483s.
31. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-47. (Pubitemid 36297053)
32. Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011;63(10-11):943-55. doi:10.1016/j.addr.2011.05.021.
33. de la Fuente M, Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine. 2008;3(6):845-57. doi:10.2217/17435889.3.6.845.
34. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. Official J Controlled Release Soc. 2008;125(3):193-209. doi:10.1016/j.jconrel.2007.09.013.
35. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. Official J Controlled Release Soc. 2001;70(1-2):1-20. (Pubitemid 32144788)
36. Zhang XQ, Intra J, Salem AK. Conjugation of polyamidoamine dendrimers on biodegradable microparticles for nonviral gene delivery. Bioconjug Chem. 2007;18(6):2068-76. doi:10.1021/bc070116l. (Pubitemid 350220010)
37. Liu J, Zhang SM, Chen PP, Cheng L, Zhou W, Tang WX, et al. Controlled release of insulin from PLGA nanoparticles embedded within PVA hydrogels. J Mater Sci Mater Med. 2007;18(11):2205-10. doi:10.1007/s10856-007-3010-0. (Pubitemid 350167371)
38. Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. International J Pharm. 2007;334(1-2):137-48. doi:10.1016/j. ijpharm.2006.10.036. (Pubitemid 46400322)
39. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. Official J Controlled Release Soc. 2009;133(2):90-5. doi:10.1016/j.jconrel.2008.09.073.
40. Allemann E, Leroux JC, Gurny R, Doelker E. In vitro extend-edrelease properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res. 1993;10(12):1732-7. (Pubitemid 24000357)
41. Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, et al. Polymer degradation and in vitro release of a model protein from poly(D, L-lactide-co-glycolide) nano- and microparticles. Official J Controlled Release Soc. 2003;92(1-2):173-87. (Pubitemid 37130131)
42. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15(5-6):171-85. doi:10.1016/j.drudis.2010.01.009.
43. Jevprasesphant R, Penny J, Attwood D, McKeown NB, D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res. 2003;20(10):1543-50. (Pubitemid 37268266)
44. Csaba N, Caamano P, Sanchez A, Dominguez F, Alonso MJ. PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery. Biomacromolecules. 2005;6(1):271-8. doi:10.1021/bm049577p. (Pubitemid 40277024)
45. Ehrhardt C, Fiegel J, Fuchs S, Abu-Dahab R, Schaefer UF, Hanes J, et al. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. Official J International Soc Aero Med. 2002;15(2):131-9. doi:10.1089/089426802320282257. (Pubitemid 34827526)
46. Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Development Indus Pharm. 2010;36(10):1207-14. doi:10.3109/ 03639041003695113.
47. Madlova M, Jones SA, Zwerschke I, Ma Y, Hider RC, Forbes B. Poly(vinyl alcohol) nanoparticle stability in biological media and uptake in respiratory epithelial cell layers in vitro. Official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2009;72(2):437-43. doi:10.1016/j.ejpb. 2009.01.009.
48. El-Sayed M, Ginski M, Rhodes C, Ghandehari H. Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. Official J Controlled Release Soc. 2002;81(3):355-65. (Pubitemid 34607155)
49. Kitchens KM, Kolhatkar RB, Swaan PW, Eddington ND, Ghandehari H. Transport of poly (amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling. Pharm Res. 2006;23(12):2818-26. doi:10.1007/s11095-006-9122-2. (Pubitemid 44885368)
50. Tajarobi F, El-Sayed M, Rege BD, Polli JE, Ghandehari H. Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells. International J Pharm. 2001;215(1-2):263-7. (Pubitemid 32206623)
51. Mura S, Hillaireau H, Nicolas J, Kerdine-Romer S, LeDroumaguet B, Delomenie C, et al. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules. 2011;12(11):4136-43. doi:10.1021/bm201226x.
52. Seib FP, Jones AT, Duncan R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10melanoma cells. Official J Controlled Release Soc. 2007;117(3):291-300. doi:10.1016/j.jconrel. 2006.10.020. (Pubitemid 46216575)
53. D'Emanuele A, Attwood D. Dendrimer- drug interactions. Adv Drug Deliv Rev. 2005;57(15):2147-62. doi:10.1016/j.addr.2005.09.012.
54. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A. 2009;106(46):19268-73. doi:10.1073/pnas.0905998106.
55. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cel l Molec Life Sc i . 2009;66(17):2873-96. doi:10.1007/s00018-009-0053-z.
56. Bucior I, Mostov K, Engel JN. Pseudomonas aeruginosamediated damage requires distinct receptors at the apical and basolateral surfaces of the polarized epithelium. Infec Immu. 2010;78(3):939-53. doi:10.1128/IAI.01215-09.
57. Bharatwaj B, Wu L, Whittum-Hudson JA, da Rocha SR. The potential for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the treatment of Chlamydial respiratory infections. Biomaterials. 2010;31(28):7376-85. doi:10.1016/j.biomaterials.2010.06.005.
58. Wu L, Peguin RP, da Rocha SR. Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy. J Phys Chem B. 2007;111(28):8096-104. doi:10.1021/ jp071205y.
59. Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. The official Journal International Society Aerosols Medicine. 2003;16(4):341-77. doi:10.1089/089426803772455622.